?? Join us on Thursday, Dec. 5, for a webinar on the implications of the Inflation Reduction Act on pricing negotiations for your product portfolio. Gain valuable insights from our experts Haripriya Jain, Ariel Berger and Sarah Ronnebaum as they offer perspectives around evidence strategies to help manufacturers demonstrate product value for #Medicare price negotiations. Register now! ? https://bit.ly/4hLHSG8 #IRA #InflationReductionAct #DrugPricing #MaximumFairPrice #MFP
Evidera
研究服务
Bethesda,MD 24,808 位关注者
Evidera, a PPD business specializing in evidence, value, and access
关于我们
Evidera is a business within Pharmaceutical Product Development, LLC, (PPD) a leading global contract research organization (CRO), and is the preeminent provider of evidence-based solutions to demonstrate the real-world effectiveness, safety, and value of biopharmaceutical and biotechnology products from early development through loss of exclusivity. We provide integrated scientific expertise and global operational capabilities to help you generate the evidence needed to optimize the market access and commercial potential of your products. Evidera was acquired by PPD in 2016 and originally created in 2013 as an independent company under the ownership of Symphony Technology Group following the acquisition of long-standing health economics, outcomes research, market access, epidemiology, and data analytics practices from United BioSource Corporation (UBC). Evidera has over 30 years of leadership and experience and its legacy brands include MEDTAP, Caro Research, Abt Bio-Pharmaceutical Solutions, MetaWorks, Total Healthcare Group, and Archimedes.
- 网站
-
https://www.evidera.com/
Evidera的外部链接
- 所属行业
- 研究服务
- 规模
- 501-1,000 人
- 总部
- Bethesda,MD
- 类型
- 私人持股
- 创立
- 2013
- 领域
- Life Sciences、Consulting、Evalytica (evalytica.com)、Meta Research、Modeling and Simulation、Outcomes Research、Market Access Communications、Market Access Consulting、Real-World Evidence: Data Collection & Analytics、Value & Evidence Planning、Patient-Centered Research、Interventional Studies、Pragmatic Studies、Medical Writing and Healthcare Communications、Health Economics和Epidemiology
地点
Evidera员工
动态
-
Join us at #ISPOREurope in Barcelona on Nov. 17-20! Connect with our experts to explore how our expertise in #RWD, #RWE, market access and patient engagement strategies can drive innovation in #HEOR. ?? Schedule a meeting. ? https://bit.ly/3YsORuX
-
Attending the DIA Real-World Evidence Conference? Don't miss Delphine Saragoussi, MD, MScPH , executive director, epidemiology and scientific affairs, as she speaks on test-negative design studies during session 7 on Friday, Oct. 25. Learn more about our work. ? https://bit.ly/3pSoAZo #rwe #epidemiology
-
Meet us at #WVCEU! Our team is eager to discuss your unique challenges. Discover how leveraging #realworlddata, #realworldevidence and our global resources can unlock the full potential of your vaccine program. Visit us at booth 69 or attend our Working Group on Wednesday, Oct. 30 with Delphine Saragoussi, MD, MScPH , Sarah Rosen, Javier Cid and Narcisa MESAROS, MD. ? https://bit.ly/3BTJRrK
-
Save your spot for our Patient Preference Insights Meetup at #ISPOREurope! Network with peers and industry experts, enjoy great food and dive into discussions on how patient preference studies inform regulatory and HTA engagements, amplifying patient voices in decision-making. ?? Don't miss out. Register today! ? https://bit.ly/4eLR8by
-
Join us for a dynamic workshop and networking event at ISPOR EU focused on navigating EU HTA Regulation changes. Discover our integrated framework to enhance your product development strategy in this evolving EU market access landscape. ?? RSVP today! ? https://bit.ly/4f64HlK
-
Evidera转发了
The COPD Foundation’s PIVOT initiative is leading the way in ensuring patient perspectives and priorities are integrated into the development of COPD treatments. We strongly believe that this integration will lead to faster, more efficient drug development, earlier access to new treatments, and clearer communication about treatment benefits that will help COPD patients and their doctors make decisions together. In collaboration with our research partner, Evidera, we are developing a unified set of patient-inspired health concepts representing the effects of COPD on how patients feel or function, which will be a north star for identifying, testing, and communicating treatment benefit. The development of a unified set of patient-inspired health concepts requires high-quality qualitative and quantitative research, systematic and robust methods of patient engagement, and a rigorous process for building consensus among patients, clinical and research experts, and regulators. Special thanks to our PIVOT sponsors (PIVOT Industry Expert Forum members) for their support in 2024! If you are interested in being involved in PIVOT, please contact: [email protected].
-
We are having great discussions and meeting lots of new people at #ISPEAnnual2024 in Berlin! Stop by booth 401 to speak with our team or engage in interesting conversation about the use of registry data in studies, the latest in pregnancy and lactation research, and #RWDE. Join our Tuesday afternoon sessions: Delphine Saragoussi will speak on novel individualized therapeutics and the use of #RWE in rare diseases, and Meredith Smith will outline why RWE studies need implementation research.
-
Meet our team at #ISPEAnnual2024 in Berlin on Aug. 24-28! Find our colleagues at booth 401, where we're excited to meet you and discuss the latest advancements in #epidemiology, safety and #RWDE. We’re also presenting throughout the conference. We encourage you to attend those sessions and meet with our experts. Book a meeting with us to explore how we can support your #realworldevidence needs: https://bit.ly/45ov1mx
-
Join our webinar on Wednesday, September 11 to explore the advantages of utilizing in-trial interview data in drug development. Carla Dias Barbosa, Miriam Kimel, Karen Bailey, PhD and Paulina Rolska-Wójcik will discuss how qualitative evidence enhances clinical trials, influences regulatory evaluations and affects health technology assessments and reimbursement decisions. Register now! ? https://bit.ly/4fVmKwm #clinicaltrials #HTA